|The following article features coverage from the American Society of Clinical Oncology 2020 virtual meeting. Click here to read more of Oncology Nurse Advisor‘s conference coverage.
A novel, wearable monitoring platform for patients with advanced age and cancer allowed for additional assessment of health. These findings, from a prospective single center, single arm study, were presented during the ASCO20 Virtual Scientific Program.
The Sensing in At-Risk Populations (SARP) monitoring platform consisted of a smartwatch, software, and centralized data processing. These data were used to determine treatment-related adverse effects and correlations with hospitalizations. The 26 recruited patients were older than 60 years and actively undergoing therapy for cancer. The participants were instructed use SARP for 7 days or longer between 2016 and 2017.
The average patient age was 72 years and most participants were male (69.2%). For 12 patients the Eastern Cooperative Oncology Group Performance Status (ECOG PS) was 0, 12 had a PS of 1, and the remaining 2 had a PS of 2.
Using the Cancer and Ageing Research Group (CARG) chemotherapy toxicity score, 4 patients were scored as low, 17 as intermediate, and 3 as high toxicity. These scores were significantly correlated with dose delay (effect size, 0.45; P =.05) and dose reduction (effect size, 0.40; P =.05). The patient’s energy intensity was significantly correlated with emergency room visits, with an effect size of 0.95 (P =.04).
A limitation of this study was the small sample size and short study duration, the presenting authors noted that additional cohorts are currently enrolled in a home-based monitoring program.
The presenters concluded that their SARP platform gave clinicians a supplementary opportunity to monitor patient health and assess risk in patients of advanced age undergoing treatment for cancer.
Disclosure: One author declared affiliations with industry. Please refer to the original abstract for a full list of disclosures.
Wong K, Shen J, Ramezani R, et al. A pilot study of a wearable monitoring system as an adjunct to geriatric assessment in older adults with cancer. Presented at: ASCO20 Virtual Scientific Program. J Clin Oncol. 2020;38(suppl):abstr 2062.